During the past decade, Universitätsfrauenklinik Köln conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 1 clinical trials were completed, i.e. on
average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer
Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer
2018-09-11
2024-12-01
Active, not recruiting
550
Clinical Trials Sponsors and Collaborators
In terms of collaborators to trials, out of the total clinical trials conducted in "Universitätsfrauenklinik Köln"
#1 collaborator was "Hoffmann-La Roche" with 2 trials as a collaborator, "Arbeitsgemeinschaft Gynaekologische Onkologie Austria" with 1 trials as a collaborator, "Arbeitsgemeinschaft Gynaekologishe Onkologie Germany" with 1 trials as a collaborator, "Belgian Gynaecological Oncology Group" with 1 trials as a collaborator and "Breast International Group" with 1 trials as a collaborator. Other collaborators include 1 different institutions and companies that were
collaborators in the rest 11 trials.
Clinical Trials Conditions at Universitätsfrauenklinik Köln
According to Clinical.Site data, the most researched conditions in "Universitätsfrauenklinik Köln" are
"Breast Cancer" (1 trials), "Neoplasm Metastasis" (1 trials), "Ovarian Cancer" (1 trials) and "Recurrent Ovarian Carcinoma" (1 trials). Many other conditions were trialed in "Universitätsfrauenklinik Köln" in a lesser frequency.
Clinical Trials Intervention Types at Universitätsfrauenklinik Köln
Most popular intervention types in "Universitätsfrauenklinik Köln" are "Drug" (4 trials). Other intervention types were less common.
The name of intervention was led by "Atezolizumab" (2 trials), "Docetaxel" (2 trials), "Paclitaxel" (2 trials), "Pertuzumab" (2 trials) and "Placebo" (2 trials). Other intervention names were less common.
Clinical Trials Genders at Universitätsfrauenklinik Köln
The vast majority of trials in "Universitätsfrauenklinik Köln" are
2 trials for "All" genders and 2 trials for "Female" genders.
Clinical Trials Status at Universitätsfrauenklinik Köln
Currently, there are NaN active trials in "Universitätsfrauenklinik Köln".
undefined are not yet recruiting,
1 are recruiting,
2 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 1 completed trials in Universitätsfrauenklinik Köln,
undefined suspended trials,
and undefined terminated clinical trials to date.
Out of the total trials that were conducted in Universitätsfrauenklinik Köln, 0 "Phase 1"
clinical trials were conducted, 1 "Phase 2" clinical
trials and 3 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".